Allakos(ALLK)

1.025 0.005 0.49%

今开:1.01昨收:1.02
最高:1.045 最低:0.9799
涨停价:0.0跌停价:0.0
总市值:9.0758086E7

Allakos的热门讨论

超过5%股东持股披露「修订」

Allakos(ALLK)02-03 01:35

$Allakos(ALLK)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-022661  Act: 34  Size: 374 KB 网页链接查看全文

当期报告

Allakos(ALLK)02-03 05:15

$Allakos(ALLK)$ 8-K Current report, item 7.01 Accession Number: 0000950170-24-010473  Act: 34  Size: 148 KB 网页链接查看全文

首次持股声明

Allakos(ALLK)01-27 06:25

$Allakos(ALLK)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000921895-24-000148  Size: 24 KB 网页链接查看全文

首次持股声明

Allakos(ALLK)02-17 08:15

$Allakos(ALLK)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-24-003482  Size: 7 KB 网页链接查看全文

证券出售报告

Allakos(ALLK)03-07 05:15

$Allakos(ALLK)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-002012  Act: 33  Size: 4 KB 网页链接查看全文

持股变动声明

Allakos(ALLK)02-22 06:05

$Allakos(ALLK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-24-003676  Size: 5 KB 网页链接查看全文

持股变动声明

Allakos(ALLK)02-22 06:05

$Allakos(ALLK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-24-003675  Size: 5 KB 网页链接查看全文

股东委托书协议

Allakos(ALLK)04-24 05:15

$Allakos(ALLK)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-047043  Act: 34  Size: 4 MB 网页链接查看全文

证券出售报告

Allakos(ALLK)03-05 06:55

$Allakos(ALLK)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-001797  Act: 33  Size: 5 KB 网页链接查看全文

超过5%股东持股披露

Allakos(ALLK)01-27 05:25

$Allakos(ALLK)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-000349  Act: 34  Size: 102 KB 网页链接查看全文

1 2 3

Allakos的新闻

目标价从230美元被砍至20美元,Allakos(ALLK.US)怎么了?

智通财经APP获悉,Allakos(ALLK.US)股价在盘前下跌近3%,此前H.C. Wainwright分析师Patrick Trucchio将Allakos目标股价从230美元下调至20美元,但维持“买入”评级。 在上周,该公司公布了lirentelimab在活检被证实为嗜酸细胞性胃炎和/... 网页链接

临床阶段生物技术公司Allakos(ALLK)美股盘初崩跌87.6%

临床阶段生物技术公司Allakos(ALLK)美股盘初崩跌87.6%,拖累纳斯达克生物科技指数跌超1.0%,并领跌罗素2000指数的成分股。周二美股盘后,该公司宣布,Enigma 2研究未能实现统计学意义,但Enigma 2和Kryptos研究实现了公司的主要终点。 网页链接

Allakos的公告

其他

$Allakos(ALLK)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-047072  Act: 34  Size: 2 MB 网页链接

股东委托书协议

$Allakos(ALLK)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-047043  Act: 34  Size: 4 MB 网页链接

当期报告

$Allakos(ALLK)$ 8-K Current report, item 5.02 Accession Number: 0000950170-24-047061  Act: 34  Size: 148 KB 网页链接

证券出售报告

$Allakos(ALLK)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-002494  Act: 33  Size: 6 KB 网页链接

当期报告

$Allakos(ALLK)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-031496  Act: 34  Size: 347 KB 网页链接

年度财报

$Allakos(ALLK)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-031516  Act: 34  Size: 12 MB 网页链接

持股变动声明

$Allakos(ALLK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-028122  Size: 4 KB 网页链接

持股变动声明

$Allakos(ALLK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-027393  Size: 5 KB 网页链接

持股变动声明

$Allakos(ALLK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-027392  Size: 5 KB 网页链接

证券出售报告

$Allakos(ALLK)$ 144 Report of proposed sale of securities Accession Number: 0001959173-24-002012  Act: 33  Size: 4 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48